Panacos begins early stage HIV inhibitor study
This phase I study is designed to evaluate the safety and pharmacokinetic properties of the inhibitor PA-040 in humans after a single dose. Maturation inhibition is a new
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.